Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Over the next two weeks EXAS will have its annual meeting and second-quarter webcast. The big tell for me will be the growth in quarterly tests completed for Cologuard. Results in this area will solidify if the test is considered effective by physicians and payers (insurers), which is critical for the ongoing steps towards profitability.

What is of greater importance, though, will be insights into research being performed and strategic alliances in those areas. Because of the nature of these endeavors there may be little of anything that can be discussed. From a numbers perspective, though, the continued percentage of revenue directed towards research is telling as to the focus of the company. I am not expecting profitability in the near term, but I am expecting a disciplined approach to moving the company in that direction.

Jim

Full disclosure - EXAS is my largest holding based on value, but after having trimmed some shares, it is no longer my largest holding based on initial investment (net of investments made versus shares sold). I am still considering one additional sale which will take my investment cost down to zero while still retaining a substantial (for me at least) position.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.